Johnson & Johnson Q3 Earnings Review: Nicely Poised For Steady Growth (Upgrade)Seeking Alpha • 10/17/24
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?The Motley Fool • 10/16/24
Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & JohnsonBusiness Wire • 10/15/24
J&J must pay $15 mln to Connecticut man who says its talc gave him cancer, jury findsReuters • 10/15/24
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS GuidanceZacks Investment Research • 10/15/24
Johnson & Johnson Posts Weaker-Than-Expected Profit on Billions in Legal CostsInvestopedia • 10/15/24
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 10/15/24
Johnson & Johnson Earnings Top; Dow Giant Falls Amid Lowered OutlookInvestors Business Daily • 10/15/24
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 studyPRNewsWire • 10/15/24